Table 2.
Parameters | Increasing hydrophilic content → | ||||
---|---|---|---|---|---|
Types of lipid formulations | |||||
Type I | Type II | Type IIIA | Type IIIB | Type IV | |
Example/reference | [30] | [31] | [19] | [32] | [29] |
| |||||
Triglycerides or mixed glycerides (%w/w) | 100 | 40–80 | 40–80 | <20 | — |
| |||||
Water-insoluble surfactants (%w/w) (HLB < 12) | — | 20–60 | — | — | 0–20 |
| |||||
Water-soluble surfactants (%w/w) (HLB > 11) | — | — | 20–40 | 20–50 | 30–80 |
| |||||
Hydrophilic cosolvents (%w/w) |
— | — | 0–40 | 20–50 | 0–50 |
| |||||
Particle size of dispersion (nm) | Coarse | 250–2000 | 100–250 | 50–100 | <50 |
| |||||
Characteristics | Nondispersing | SEDDS without water-soluble components | SEDDS/SMEDDS with water-soluble components | SMEDDS with water-soluble components and low oil content. | Oil-free formulations |
| |||||
Significance of aqueous dilution |
Limited importance | Solvent capacity unaffected | Some loss of solvent capacity | Significant phase changes and potential loss of solvent capacity | — |
| |||||
Significance of digestibility | Crucial requirement | Not crucial but likely to occur | Not crucial but may be inhibited. | Not required and not likely to occur | Not likely to occur |
| |||||
Advantages | GRAS status; simple; excellent capsule compatibility | Unlikely to lose solvent capacity on dispersion | Clear or almost clear dispersion. Absorption without digestion | Clear dispersion. Absorption without digestion | Good solvent capacity for many drugs; disperse to micellar solution |
| |||||
Disadvantages | Poor solvent capacity (unless drug is highly lipophilic) | Turbid o/w dispersion | Possible loss of solvent capacity on dispersion. Less easily digested | Likely loss of solvent capacity on dispersion | Loss of solvent capacity on dispersion; may not be digestible |